Genomic testing in lung cancer: The search for oncogenic drivers
20 Nov 2024
About the event
This educational webinar welcomes an expert faculty to discuss the current genomic testing pathways used in the UK to characterise oncogenic drivers in lung cancer and the factors to consider when carrying out these tests and interpreting the results. The faculty will also delve into real-world data; highlighting the importance of identifying oncogenic drivers with correct and timely testing to optimise treatment pathways.
Merck is a global science and technology company with a passion for forward-thinking discoveries. We want to develop products and solutions for a better life. That's why we take a closer look at things, ask questions and think ahead.
More than 52,000 employees in 66 countries work together with us on innovative solutions and the newest technologies in healthcare, life science and performance materials. From improving electronic devices with smarter materials to generating ultra pure water, testing the quality of food and drugs, and treating cancer, Merck always promotes opportunities to break new ground.
